Literature DB >> 20535762

Strength of evidence of non-inferiority trials-The adjustment of the type I error rate in non-inferiority trials with the synthesis method.

Seung-Ho Kang1, Yi Tsong.   

Abstract

In non-inferiority trials that employ the synthesis method several types of dependencies among test statistics occur due to sharing of the same information from the historical trial. The conditions under which the dependencies appear may be divided into three categories. The first case is when a new drug is approved with single non-inferiority trial. The second case is when a new drug is approved if two independent non-inferiority trials show positive results. The third case is when two new different drugs are approved with the same active control. The problem of the dependencies is that they can make the type I error rate deviate from the nominal level. In order to study such deviations, we introduce the unconditional and conditional across-trial type I error rates when the non-inferiority margin is estimated from the historical trial, and investigate how the dependencies affect the type I error rates. We show that the unconditional across-trial type I error rate increases dramatically as does the correlation between two non-inferiority tests when a new drug is approved based on the positive results of two non-inferiority trials. We conclude that the conditional across-trial type I error rate involves the unknown treatment effect in the historical trial. The formulae of the conditional across-trial type I error rates provide us with a way of investigating the conditional across-trial type I error rates for various assumed values of the treatment effect in the historical trial. (c) 2010 John Wiley & Sons, Ltd.

Mesh:

Year:  2010        PMID: 20535762     DOI: 10.1002/sim.3903

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  3 in total

1.  A simulation study evaluating bio-creep risk in serial non-inferiority clinical trials for preservation of effect.

Authors:  K Odem-Davis; T R Fleming
Journal:  Stat Biopharm Res       Date:  2015-01-01       Impact factor: 1.452

2.  On robustness of noninferiority clinical trial designs against bias, variability, and nonconstancy.

Authors:  Qing Liu; Yulan Li; Katherine Odem-Davis
Journal:  J Biopharm Stat       Date:  2015       Impact factor: 1.051

3.  Bayesian Design of Non-Inferiority Clinical Trials via the Bayes Factor.

Authors:  Wenqing Li; Ming-Hui Chen; Xiaojing Wangy; Dipak K Dey
Journal:  Stat Biosci       Date:  2017-07-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.